Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Refinement of Immunohistologic Parameters for Her2/neu Scoring Validation by FISH and CISH

Refinement of Immunohistologic Parameters for Her2/neu Scoring Validation by FISH and CISH RESEARCH ARTICLE Refinement of Immunohistologic Parameters for Her2/neu Scoring Validation by FISH and CISH Anthony S-Y Leong, MB, BS, MD, FRCPA, FRCPath, FCAP,* Mark Formby, MB, BS, FRCPA,* Zenobia Haffajee, HT,* Megan Clarke, HT,* and Adrienne Morey, MB, BS, FRCPAw ality, Herceptin acts at the protein and not at the gene Abstract: The conventional method of scoring Her2/neu level, and there is accumulating data to show response to immunostaining is recognized to result in a high false-positive Herceptin in patients with positive IHC whether or not 2,3 rate among 2+ cases when compared with results obtained with gene amplification is present. The latter observations fluorescence in situ hybridization (FISH); however, costs and suggest the existence of alternative mechanism of protein convenience dictates that immunohistochemistry remains the overexpression other than gene amplification. Although screening test for Her2/neu status in patients with breast cancer. both methods of assaying Her2/neu need to be carried out We describe refined criteria for scoring of Her2/neu on the basis by experienced laboratories to achieve consistency, it has of anatomic localization rather than the subjective assessment of been argued that IHC results also vary with interpretative intensity. The presence of a circumferential tram track pattern skills. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Refinement of Immunohistologic Parameters for Her2/neu Scoring Validation by FISH and CISH

Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/refinement-of-immunohistologic-parameters-for-her2-sol-neu-scoring-Tx3stw0tAe

References (25)

ISSN
1541-2016
DOI
10.1097/01.pai.0000210415.53493.d4
pmid
17122633
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Refinement of Immunohistologic Parameters for Her2/neu Scoring Validation by FISH and CISH Anthony S-Y Leong, MB, BS, MD, FRCPA, FRCPath, FCAP,* Mark Formby, MB, BS, FRCPA,* Zenobia Haffajee, HT,* Megan Clarke, HT,* and Adrienne Morey, MB, BS, FRCPAw ality, Herceptin acts at the protein and not at the gene Abstract: The conventional method of scoring Her2/neu level, and there is accumulating data to show response to immunostaining is recognized to result in a high false-positive Herceptin in patients with positive IHC whether or not 2,3 rate among 2+ cases when compared with results obtained with gene amplification is present. The latter observations fluorescence in situ hybridization (FISH); however, costs and suggest the existence of alternative mechanism of protein convenience dictates that immunohistochemistry remains the overexpression other than gene amplification. Although screening test for Her2/neu status in patients with breast cancer. both methods of assaying Her2/neu need to be carried out We describe refined criteria for scoring of Her2/neu on the basis by experienced laboratories to achieve consistency, it has of anatomic localization rather than the subjective assessment of been argued that IHC results also vary with interpretative intensity. The presence of a circumferential tram track pattern skills.

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Dec 1, 2006

There are no references for this article.